PMV Pharmaceuticals Stock Forecast, Price & News

PMV Pharmaceuticals (NASDAQ:PMVP) Frequently Asked Questions

Is PMV Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PMV Pharmaceuticals stock.
View analyst ratings for PMV Pharmaceuticals or view top-rated stocks.

Are investors shorting PMV Pharmaceuticals?

PMV Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 3,700,000 shares, an increase of 18.2% from the December 15th total of 3,130,000 shares. Based on an average trading volume of 430,500 shares, the days-to-cover ratio is presently 8.6 days. Currently, 13.4% of the shares of the stock are short sold.
View PMV Pharmaceuticals' Short Interest.

When is PMV Pharmaceuticals' next earnings date?

PMV Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for PMV Pharmaceuticals.

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.03.
View PMV Pharmaceuticals' earnings history.

What price target have analysts set for PMVP?

4 Wall Street analysts have issued 12 month price objectives for PMV Pharmaceuticals' shares. Their forecasts range from $43.00 to $62.00. On average, they expect PMV Pharmaceuticals' stock price to reach $53.67 in the next twelve months. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for PMV Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are PMV Pharmaceuticals' key executives?

PMV Pharmaceuticals' management team includes the following people:

• Dr. David H. Mack, Co-Founder, CEO, Pres & Director (Age 59, Pay $770.33k)
• Dr. Arnold J. Levine Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 81, Pay $110k)
• Mr. Winston Kung, COO & CFO (Age 45, Pay $608.93k) (LinkedIn Profile)
• Dr. Leila Alland, Chief Medical Officer (Age 58, Pay $629.67k) (LinkedIn Profile)
• Dr. Thomas E. Shenk Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 74)
• Mr. Robert Ticktin, Gen. Counsel & Company Sec. (Age 59)
• Dr. Deepika Jalota Pharm.D., Chief Regulatory & Quality Assurance Officer (Age 44)

Who are some of PMV Pharmaceuticals' key competitors?

Some companies that are related to PMV Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Pacira BioSciences (PCRX), Amicus Therapeutics (FOLD), Cytokinetics (CYTK), Insmed (INSM), Zentalis Pharmaceuticals (ZNTL), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), I-Mab (IMAB), EQRx (EQRX), Arcus Biosciences (RCUS), OPKO Health (OPK) and Indivior (INVVY).
View all of PMVP's competitors.

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

When did PMV Pharmaceuticals IPO?

(PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is PMV Pharmaceuticals' stock symbol?

PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Asymmetry Capital Management L.P. (0.22%). Company insiders that own PMV Pharmaceuticals stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Paul Klauder, Ra Capital Management, LP, Richard A Heyman, Thilo Schroeder and Winston Kung.
View institutional ownership trends for PMV Pharmaceuticals.

Which institutional investors are selling PMV Pharmaceuticals stock?

PMVP stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P.. Company insiders that have sold PMV Pharmaceuticals company stock in the last year include Arnold J Levine, David Henry Mack, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Paul Klauder, Richard A Heyman, Thilo Schroeder, and Winston Kung.
View insider buying and selling activity for PMV Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PMV Pharmaceuticals' stock price today?

One share of PMVP stock can currently be purchased for approximately $17.36.

How much money does PMV Pharmaceuticals make?

PMV Pharmaceuticals has a market capitalization of $787.80 million. The company earns $-34.44 million in net income (profit) each year or $2.65 on an earnings per share basis.

How many employees does PMV Pharmaceuticals have?

PMV Pharmaceuticals employs 44 workers across the globe.

What is PMV Pharmaceuticals' official website?

The official website for PMV Pharmaceuticals is www.pmvpharma.com.

How can I contact PMV Pharmaceuticals?

The company can be reached via phone at 609-642-6670 or via email at [email protected].